JP2025509818A5 - - Google Patents
Info
- Publication number
- JP2025509818A5 JP2025509818A5 JP2024555324A JP2024555324A JP2025509818A5 JP 2025509818 A5 JP2025509818 A5 JP 2025509818A5 JP 2024555324 A JP2024555324 A JP 2024555324A JP 2024555324 A JP2024555324 A JP 2024555324A JP 2025509818 A5 JP2025509818 A5 JP 2025509818A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- ppm
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323005P | 2022-03-23 | 2022-03-23 | |
| US63/323,005 | 2022-03-23 | ||
| PCT/IB2023/052709 WO2023180898A1 (en) | 2022-03-23 | 2023-03-20 | Crystalline salt form of a shp2 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509818A JP2025509818A (ja) | 2025-04-11 |
| JP2025509818A5 true JP2025509818A5 (enExample) | 2026-02-12 |
Family
ID=85724850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024555324A Pending JP2025509818A (ja) | 2022-03-23 | 2023-03-20 | Ｓｈｐ２阻害剤の結晶性塩形態 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250214966A1 (enExample) |
| EP (1) | EP4496629A1 (enExample) |
| JP (1) | JP2025509818A (enExample) |
| KR (1) | KR20240163705A (enExample) |
| CN (1) | CN119095836A (enExample) |
| AR (1) | AR128847A1 (enExample) |
| AU (1) | AU2023238523B2 (enExample) |
| CA (1) | CA3256136A1 (enExample) |
| MX (1) | MX2024011603A (enExample) |
| TW (1) | TW202346282A (enExample) |
| WO (1) | WO2023180898A1 (enExample) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021002880A (es) | 2018-09-14 | 2021-06-04 | Unilever Ip Holdings B V | Evaluacion de la eficacia de composiciones cosmeticas que no se deben enjuagar para proteger la piel de los contaminantes. |
| IL320682A (en) * | 2019-04-02 | 2025-07-01 | Array Biopharma Inc | Protein tyrosine phosphatase inhibitors |
-
2023
- 2023-03-20 KR KR1020247034661A patent/KR20240163705A/ko active Pending
- 2023-03-20 CN CN202380027478.0A patent/CN119095836A/zh active Pending
- 2023-03-20 MX MX2024011603A patent/MX2024011603A/es unknown
- 2023-03-20 EP EP23712623.0A patent/EP4496629A1/en active Pending
- 2023-03-20 WO PCT/IB2023/052709 patent/WO2023180898A1/en not_active Ceased
- 2023-03-20 AU AU2023238523A patent/AU2023238523B2/en active Active
- 2023-03-20 CA CA3256136A patent/CA3256136A1/en active Pending
- 2023-03-20 US US18/848,662 patent/US20250214966A1/en active Pending
- 2023-03-20 JP JP2024555324A patent/JP2025509818A/ja active Pending
- 2023-03-22 AR ARP230100698A patent/AR128847A1/es unknown
- 2023-03-22 TW TW112110698A patent/TW202346282A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024513798A5 (enExample) | ||
| ES2670416T3 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento de cáncer | |
| JP2024512624A (ja) | Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン | |
| CN110317214B (zh) | 作为蛋白质激酶的调节剂的二芳基巨环 | |
| JP2022058395A5 (enExample) | ||
| TWI616449B (zh) | 洛拉替尼（ｌｏｒｌａｔｉｎｉｂ）游離鹼的晶型 | |
| AU2022252094B2 (en) | Crystalline form of a shp2 inhibitor | |
| AU2018306328A1 (en) | Macrocyclic compounds and uses thereof | |
| US11084786B2 (en) | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | |
| CA3211110A1 (en) | 4-aminoquinazoline compound | |
| JP2017537114A5 (enExample) | ||
| JP2008505167A5 (enExample) | ||
| RU2010142396A (ru) | Кристаллические формы и две сольватные формы солей молочной кислоты 4-амино-5-фтор-3-[5-(4-метилпиперазин-1-ил)-1-н-бензимидазол-2-ил] хинолин-2(1н)она | |
| RU2022109286A (ru) | Кристаллическая форма гидрата свободного основания лорлатиниба | |
| JP2008528470A5 (enExample) | ||
| EP4186906A1 (en) | Compound as brain-permeable btk or her2 inhibitor, preparation method therefor, and use thereof | |
| JPWO2020032105A5 (enExample) | ||
| JP2024545073A5 (enExample) | ||
| ES2887261T3 (es) | Compuestos de fenoxiquinazolina y su uso para tratar el cáncer | |
| RU2024127743A (ru) | Кристаллическая солевая форма ингибитора shp2 | |
| JP2022500456A (ja) | キナゾリン化合物及びその塩酸塩の結晶形 | |
| AU2024353668A1 (en) | Cbl-b inhibitors and methods of uses thereof | |
| EP3679932A1 (en) | METHOD FOR TREATING CANCER BY COMBINATION OF Trk INHIBITOR AND KINASE INHIBITOR | |
| Jiang et al. | Recent advances in Pyrazolo [3, 4-d] pyrimidine-based dual inhibitors in the treatment of cancers | |
| RU2826000C1 (ru) | 3,4-дигидро-2,7-нафтиридин-1,6(2h,7h)-дионы в качестве ингибиторов mek |